In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
 

Diabetes and heart disease

ESC webinar

Monday 06 May 2013
06/05/2013 00:00 06/05/2013 00:00 Europe/Paris Diabetes and heart disease European Society of Cardiology contact@escardio.org DD/MM/YYYY
European Society of Cardiology
Diabetes and the Heart
Chronic Nursing Care
Risk Factors and Prevention
Online
event


Watch the webinar recording

 

Lars Rydén, Christina Jarnert  and Oliver Schnell

This course focuses on diagnostic and therapeutic considerations for patients with acute coronary syndromes and with previously unknown glucose perturbations.
It will cover aspects of patient management from the acute hospitalization to secondary preventive measures during long-term follow up.

The ESC webinars are designed to help you improve your daily practice!
The format includes a case based presentation, online assesssment and live discussions with the two key opinion leaders who will deliver useful tips for your daily clinical practice.

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC)

Your questions

 Comments from Professor Rydén
Could you comment on strength of different statins in both LDL-lowering and HLD-increase Statins do usually not influence HDL cholesterol. One that may increase it somewhat is rosuvastatin. Simvastatin 40 mg has by experience a lower effect on LDL than e.g. rosuvastatin 20 mg. The use of high dosages of simva may decrease LDL but side effects start to be more common and it nay be better toi switch to a (lower) dose of a more effective statin.
Could you please repeat why is not measurable LDL-C after MI? It can be measured at admission but the nearest time thereafter it is influenced of the acute illness and is therefore better measured after a month or so.
Do we have any trials, concerning  rozuvastatin vs atorvastatin effect on events?  No there are no head-to-head comparisons.
At our institution, atorvastatin 80mg is now recommended for all post-MI patients. Is the evidence regarding this strong enough? No, all statins are useful and it is rather the impact of LDL that is important. Thus if you can reach (in a diabetes pat) a LDL of recommended value (target) the type of statin probably is of less importance.
What do You thing about role of CETP inhibitors. Proveded studies didn´t led to expected results  Just now the results are disappointing and they should not be used.
How often do you see statin-induced hepatitis? What treatment do you provide in this case? Very, very seldom of any great importance and my experience of serious such conditions is therefore not good enough to give a recommendation. Statins should be discharged of course as soon as possible and this is in mild cases enough.


Organised by

European Society of Cardiology
Address

European Society of Cardiology

European Heart House
Les Templiers
2035 Route des Colles
CS 80179 Biot

06903,  Sophia Antipolis, FR

Tel.
+33.4.92.94.76.00

Support

This programme is supported by multiple educational grants including Boehringer Ingelheim  and Sanofi in the form of unrestricted educational grants.
The ESC Webinar 2012/2013 scientific programme has not been influenced in any way by its sponsors.

Find out more
About the ESC
Press and Media
Information
Follow us

         

 Contact us

© 2020 European Society of Cardiology. All rights reserved.